1. Home
  2. ECBK vs MXCT Comparison

ECBK vs MXCT Comparison

Compare ECBK & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ECB Bancorp Inc.

ECBK

ECB Bancorp Inc.

N/A

Current Price

$21.42

Market Cap

182.5M

Sector

Finance

ML Signal

N/A

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

N/A

Current Price

$1.40

Market Cap

155.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ECBK
MXCT
Founded
1919
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
182.5M
155.8M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
ECBK
MXCT
Price
$21.42
$1.40
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $4.11
AVG Volume (30 Days)
7.4K
★ 1.4M
Earning Date
10-22-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 95.83
N/A
EPS
★ 0.77
N/A
Revenue
$598,000.00
★ $33,026,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$15.53
P/E Ratio
$27.68
★ N/A
Revenue Growth
★ 3.64
N/A
52 Week Low
$15.88
$0.64
52 Week High
$21.78
$1.81

Technical Indicators

Market Signals
Indicator
ECBK
MXCT
Relative Strength Index (RSI) 57.58 54.75
Support Level $20.03 $1.17
Resistance Level $21.58 $1.54
Average True Range (ATR) 0.49 0.13
MACD 0.11 0.01
Stochastic Oscillator 87.27 35.64

Price Performance

Historical Comparison
ECBK
MXCT

About ECBK ECB Bancorp Inc.

ECB Bancorp Inc operates as a bank holding company. The firm, through its subsidiary, engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, multifamily real estate loans, construction and land loans, and home equity lines of credit.

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

Share on Social Networks: